



BioXL
Innovative BioPharma Solutions


CancerPredict

A BioXL Initiative

Diagnostic test for improved cancer prognosis, as addition to current breast cancer screening programs

December 2024





ABOUT US

BioXL is dedicated to revolutionizing medical treatments and diagnostics by leveraging cutting-edge research and technology.

We guide our projects from the initial discovery phase all the way to clinical development. Each initiative will be created as a new company to facilitate further development and commercialization. BioXL functions as a central hub located in Sderot's startup hub, fostering innovation and collaboration.

OUR MISSION

Our mission at BioXL is to transform healthcare by developing innovative therapies that meet the needs of patients suffering from undertreated medical conditions, improving their quality of life.



OUR VISION AND VALUES

Our vision is to empower lives by providing innovative therapies that target undertreated medical needs and improve health outcomes globally.

EMPATHY

We understand and prioritize the experiences of patients and their families.

RESPONSIBILITY

We take accountability for our actions and their impact on society and the environment.

DIVERSITY

We embrace diverse perspectives to foster creativity and drive innovation.

CHALLENGE



BREAST CANCER'S GREATEST CHALLENGE LIES IN ITS SILENT PROGRESSION, WHERE SUBTLE SIGNS OFTEN GO UNNOTICED UNTIL THE DISEASE HAS ADVANCED, PUSHING THE BOUNDARIES OF OUR DIAGNOSTIC TOOLS AND DELAYING CRITICAL INTERVENTIONS

PROBLEM

THE DISEASE

Breast cancer is the most common cancer in women, except for skin cancers. It accounts for about 30% (or 1 in 3) of all new female cancers each year.

PREVALENCE

Current breast cancer risk factor screening programs lack the reliability needed to accurately predict future cancer development.

THE NUMBERS

In 2024, an estimated **310,720 women** in the United States will be diagnosed with invasive breast cancer, and **56,500 women** will be diagnosed with ductal carcinoma in situ (DCIS).

DEATHS

An estimated **42,250** will die from breast cancer in 2024.

CURRENT EARLY DIAGNOSIS

EARLY DIAGNOSIS OF CANCER CAN SIGNIFICANTLY IMPROVE TREATMENT'S OUTCOME AND INCREASE SURVIVAL RATE

- Screening testing is used for cancer detection and for evaluation of the probability of cancer development
- Risk factors assessment (family, age, BRCA gene mutation, pathology tests) provides risk score
- At high scores, women are advised to take prophylactic treatments (surgery and/or drugs)
- **However**, the predictivity of the risk assessment is far from being reliable:
 - Majority of the “high risk” women do not develop cancer
 - Many women that are “low risk” develop cancer eventually

SOLUTION

CANCERPREDICT

Novel biomarker levels in hyperplasia stage can be used for accurate cancer prognosis



BIOMARKER LEVEL IN HYPERPLASIA BIOPSY

Level of the novel biomarker expression at hyperplasia stage biopsy can potentially indicate for cancer development in future

CORRELATION

The correlation between the novel biomarker at hyperplasia and cancer development can be translated to numerical values using AI


OUTPUT

The output will be a reliable risk factor for improved prognosis of cancer development in the future

IMPROVED CANCER SCREENING AND PREDICTION

CURRENT SCREENING PROGRAM IN CONJUNCTION WITH CANCERPREDICT TEST

- Analysis of hyperplasia staged biopsy for biomarker level
- Biomarker level will be used to indicate (alone or combined with other factors) cancer development risk
- Test will output prediction of probability of cancer development in the future



MARKET POTENTIAL



OVERVIEW

CancerPredict is strategically positioned to be used as a diagnostic test for all breast cancer types, with potential for future use as a diagnostic tool in different types of cancers

\$4.96B

The global breast cancer diagnostics market size is estimated to be worth USD 4.96 billion in 2024 and is projected to reach from USD 5.30 billion in 2025 to USD 9.65 billion by 2033, growing at a CAGR of 7.62% during the forecast period (2025-2033)

CURRENT FUNDRAISING ROUND

PRE-SEED- \$250,000 USD

PRE-CLINICAL FOCUS

The funds will be used for pre-clinical studies to reach major milestone:
Confirmation of ability to predict cancer according to biomarker level in human derived biopsy samples

FUNDRAISING AND PARTNERSHIPS

Achieving these milestones is expected to attract pharma partnerships, as indicated by prior feedback, and facilitate further fundraising.

REGULATORY AND VALUATION IMPACT

At this milestone, fundraising anticipated to be enabled:
Data package will be basis for pre-IND meeting with FDA and increased Company valuation

THE TECHNOLOGY

DEVELOPED BY PROF. IDO WOLF AND HIS TEAM

Prof. Wolf (MD, PhD) is currently the director of Oncology Division of Tel Aviv Medical center.

Prof. Wolf's lab in Tel Aviv Medical Center (previously in Sheba Medical Center), led by Dr. Tamar Rubinek, is responsible for many different types of cancer research.

CANCERPREDICT TEAM




Prof. Ido Wolf, MD, PhD

Inventor, Clinical Advisor
Leading scientist, worldwide, in
cancer research. Inventor of
“Klotho for cancer”. Oncology
Division Head in Tel-Aviv Sourasky
Medical center. Endocrine-
Oncology Laboratory Head



Tamar Rubinek, PhD

Scientific Advisor



Ouriel Faktor, PhD

Diagnostics QA/RA

Project Leader
(To be announced)

WHO WE ARE



BioXL has brought together scientific experts and successful business leaders who share a passion for innovating. Our team has vast experience in biological sciences and in managing business platforms.

MEET THE BIOXL
TEAM



**MEIR AZULAY,
MSC**
Founder, CEO



**AVRAHAM
LABAN, PHD**
Founder, CTO



**OURI FISCHEL,
PHD, MBA**
Founder, Business
Development



**STEPHEN SIMES,
BSC, MBA**
Board Member,
Chairman, Mentor



**TOONLEE NG,
BSC, MBA**
Board Member, Asia
Market Development



COMMITMENT

BioXL is committed to advancing medical treatments and diagnostics through innovative research and technology

DEVELOPMENT

BioXL develops its projects from discovery to clinical stage. Each project incorporates into a new company for further development and commercialization

OPERATIONS

BioXL operates as a HUB for biotechnology and biopharma startups

Bio-XL pipeline

	Discovery	Preclinical	IND enabling	Phase I	Area	Title
CancerPredict	▶				Cancer	Diagnostic test for improved cancer prognosis
CeaseCancer	▶				Cancer	Universal Anti-cancer drug as an alternative to chemotherapy
AMP Bio	▶				Anti-biotics	Anti-Microbial Peptides to treat multi-drug resistant pathogens
NES Pharma	▶				Neuro (CNS)	Delay age-related Cognitive symptoms with combination treatment
Marathon	▶				Longevity (age related diseases)	Carrier for Mitochondria in systemic administration to avoid immune response





PLEASE REACH OUT TO US
FOR THE FULL
PRESENTATION, WHICH
INCLUDES DETAILED
INFORMATION ABOUT
CANCER PREDICT

MEIR AZULAY, CEO

Email: meir.biom@gmail.com

Tel: +972-54-953-6396

Address: Ahavat Israel 9,
Sderot, Israel

WE LOOK
FORWARD TO
COLLABORATING
WITH YOU